L Owen1, A Fischer2. 1. Centre for Guidelines, National Institute for Health and Care Excellence, London, WC1V 6NA, UK. Electronic address: Lesley.owen@nice.org.uk. 2. Office of Health Economics, Southside, 105 Victoria Street, London, SW1E 6QT, UK.
Abstract
BACKGROUND: Reviews of economic evaluations of public health (PH) interventions assessed by the National Institute for Health and Care Excellence (NICE) in the periods 2005-2010 and 2011-2016 have been undertaken. This study combines these analyses, adds six further guidelines published since then, and thus provides a summary of cost-effectiveness of NICE's PH interventions to the present. METHODS: As in previous studies, economic evaluations carried out between 2005 and 2018 were categorised by the type of economic analysis used to extract and summarise base-case ICERs. A number of 'sensitivity analyses' were carried out to test the validity of the approach. RESULTS: Of 71 guidelines examined, 27 used cost utility analysis (CUA) for specific interventions, yielding 380 individual base-case ICER estimates (or 221 taking into account clustering of interventions). The median cost per quality-adjusted life-year (QALY) ICER for the 380 estimates was £1,986. Of these, 21% were cost saving, and 54% ranged from £1 to £20,000, 3% were between £20,001 and £30,000, 16% were above £30,000 and 5% were dominated. Taking clustering into account made relatively little difference to these results. Reducing the threshold from £20,000/QALY to £15,000/QALY would result in 2% of ICERs moving across the threshold. CONCLUSIONS: Seventy-five percent of PH interventions assessed were cost-effective at a threshold of £20,000 per QALY when disregarding clustering, and 68% were cost-effective when clusters were represented by a single ICER. Other analyses gave similar results for the distribution of ICERs. Limitations of the analysis are discussed. Crown
BACKGROUND: Reviews of economic evaluations of public health (PH) interventions assessed by the National Institute for Health and Care Excellence (NICE) in the periods 2005-2010 and 2011-2016 have been undertaken. This study combines these analyses, adds six further guidelines published since then, and thus provides a summary of cost-effectiveness of NICE's PH interventions to the present. METHODS: As in previous studies, economic evaluations carried out between 2005 and 2018 were categorised by the type of economic analysis used to extract and summarise base-case ICERs. A number of 'sensitivity analyses' were carried out to test the validity of the approach. RESULTS: Of 71 guidelines examined, 27 used cost utility analysis (CUA) for specific interventions, yielding 380 individual base-case ICER estimates (or 221 taking into account clustering of interventions). The median cost per quality-adjusted life-year (QALY) ICER for the 380 estimates was £1,986. Of these, 21% were cost saving, and 54% ranged from £1 to £20,000, 3% were between £20,001 and £30,000, 16% were above £30,000 and 5% were dominated. Taking clustering into account made relatively little difference to these results. Reducing the threshold from £20,000/QALY to £15,000/QALY would result in 2% of ICERs moving across the threshold. CONCLUSIONS: Seventy-five percent of PH interventions assessed were cost-effective at a threshold of £20,000 per QALY when disregarding clustering, and 68% were cost-effective when clusters were represented by a single ICER. Other analyses gave similar results for the distribution of ICERs. Limitations of the analysis are discussed. Crown
Authors: Brian Chen; Gerard A Silvestri; Jennifer Dahne; Kyueun Lee; Matthew J Carpenter Journal: J Gen Intern Med Date: 2022-01-28 Impact factor: 6.473